Key result
Chemotherapeutic agents, particularly anthracyclines and trastuzumab, are associated with significant cardiac toxicity, necessitating careful monitoring and management of left ventricular systolic dysfunction.
This review summarizes current opinions and guidelines on chemotherapy-related cardiomyopathy, focusing on cardiotoxicity from anthracyclines and trastuzumab.
Supports vigilant LV monitoring during anthracycline/trastuzumab therapy; extends guidelines while leaving optimal prevention strategies open for prospective trials.
Advances in chemotherapeutic agents have resulted in significantly improved cancer survival rates. Cardiac toxicity, however, has emerged as a leading cause of morbidity, both during and years after treatment. One of the most common manifestations of cardiotoxicity is that of heart failure and left ventricular systolic dysfunction. In this review, current opinions and guidelines in this field are discussed, with particular focus on the most common culprits, the anthracyclines, and the monoclonal antibody, trastuzumab.
No takes yet. Share an insight, caveat, or question.
Piper et al. (2015) conducted a review in Chemotherapy-related Cardiomyopathy. Chemotherapeutic agents (Anthracyclines and Trastuzumab) was evaluated. Chemotherapeutic agents, particularly anthracyclines and trastuzumab, are associated with significant cardiac toxicity, necessitating careful monitoring and management of left ventricular systolic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: